As someone with a relatively high risk appetite when it comes to investing, I’m always on the lookout for small, fast-growing companies that could deliver significant capital gains over time. All the better if these businesses also happen to be flying under most market participants’ radars.
While the past is certainly no guide to the likelihood of more success in the future, here are two that have caught my eye recently.
I’d bet that most retail investors haven’t heard of £180m cap, AIM-listed Bioventix (LSE: BVXP). Assuming the company is able to continue performing as it has over the last few years, however, this could be all set to change.
For background, it develops and supplies antibodies that are then used in blood testing machines in laboratories and hospitals. These tests are employed in fields such as fertility, cancer and heart disease.
Although the company has been fairly quiet over the last few months, October’s results for the full year to the end of June were hugely encouraging. Revenue jumped 21% to £8.8m with pre-tax profits climbing 19% to £6.9m.
Those who like to see strong balance sheets may also like to know that Bioventix was debt-free and had £7m in cash when these numbers were announced.
While dividends aren’t of much interest to a lot of growth investors, it’s worth mentioning that the small-cap returned 61p per share to holders last year — a near 20% increase on 2016/17. There was also a special dividend of 55p per share.
Perhaps unsurprisingly, Bioventix’s share price has rocketed almost 75% over the last year. Had you bought the shares when the company first listed back in 2014, you’d have multiplied your money well over five times.
The only negative with this — at least for prospective buyers — is that the stock now trades on a seriously expensive valuation of 32 times forecast earnings.
Would I buy the shares now? Probably not. The general sell-off in equities towards the end of 2018 was a reminder of the dangers of paying too much for any company, regardless of its quality. With Brexit coming next month, the possibility of stock markets becoming choppy once again is real.
That said, if markets do dip, I’m certainly not ruling out buying a slice of Bioventix at a better price.
Another company that’s been in fine form recently is D4t4 Solutions (LSE: D4T4). Ignore the questionable name for a second. Over the last year, the data solutions provider’s valuation has increased 55%.
November’s half-year results showed evidence of strong revenue growth. At just under £14m, this was almost 200% higher than over the same period in the previous year. The company also reported an adjusted pre-tax profit of £3.35m compared to a £380,000 loss in 2017.
Commenting on the company’s outlook, CEO Peter Kear reflected that the business had “a strong pipeline of opportunities” and that D4t4 was looking forward to the rest of the year “with a high degree of confidence“.
Interestingly, unlike Bioventix, the stock isn’t all that pricey for a business experiencing such growth — a little under 19 times earnings for the current year (ending 31 March).
Dividends are fairly negligible at this point (a yield of 1.2%) but these are rising fast. The interim dividend was raised 12% to 0.7p per share. There’s also no debt and a solid cash position (just over £12m at the half-year point).